Semaglutide Reverses Aortic Dysfunction in Sarcopenia via SIRT1/cGAS-STING Pathway
Background
Aging and chronic diseases often lead to sarcopenia, a progressive loss of muscle mass and function, which is increasingly recognized for its systemic impacts, including on cardiovascular health. A critical component of cardiovascular health is the proper function of the aortic endothelial cells, which line blood vessels and regulate blood flow and inflammation. Dysfunction in these cells contributes to conditions like atherosclerosis and hypertension in sarcopenia patients. This study specifically aimed to understand how Semaglutide, a GLP-1 receptor agonist, might improve aortic endothelial cell dysfunction in sarcopenia and the underlying molecular mechanisms involved.
Results
The study revealed that Semaglutide significantly improved aortic endothelial function in sarcopenic mice. Compared to untreated sarcopenic controls, Semaglutide-treated mice showed a 25% improvement in acetylcholine-induced vasodilation (a measure of endothelial function, p<0.01). This improvement was accompanied by a significant reduction in inflammatory markers, with TNF-α levels decreasing by 32% and IL-6 by 28% in aortic tissues (p<0.05 for both). Mechanistically, Semaglutide treatment led to a 2.3-fold increase in SIRT1 protein expression and a 55% reduction in the activation of the cGAS-STING pathway, indicated by decreased p-STING and IRF3 phosphorylation (p<0.001).
Why It Matters
This research highlights a novel therapeutic potential for Semaglutide beyond its established roles in diabetes and obesity, suggesting it could directly address cardiovascular complications associated with sarcopenia. The identification of the SIRT1/cGAS-STING axis provides a crucial mechanistic understanding, opening new avenues for drug targeting. This finding is significant as it suggests Semaglutide could improve vascular health in a vulnerable aging population. These results lay the groundwork for future clinical investigations into Semaglutide's utility for improving cardiovascular outcomes in sarcopenic patients, potentially leading to new treatment strategies. Further research, including human trials, is warranted to confirm these benefits.